Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Collegium Pharmaceutical has received an average analyst recommendation of "Buy", with two analysts rating it as a strong buy and an average target price of $42.33.
• The company has initiated a $150 million share buyback plan, indicating management's confidence in the stock's undervaluation.
• Recent insider trading included significant share sales by executives, resulting in a 2.51% ownership by insiders currently.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $42.3333.

Several research firms recently weighed in on COLL. HC Wainwright upgraded Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 target price for the company in a research note on Monday, August 11th. Zacks Research upgraded Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 24th. Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Collegium Pharmaceutical in a report on Saturday, September 27th.

Collegium Pharmaceutical Stock Up 1.0%

COLL stock traded up $0.33 during trading on Friday, hitting $34.61. 228,629 shares of the company's stock were exchanged, compared to its average volume of 426,576. The business has a 50-day moving average price of $35.94 and a two-hundred day moving average price of $31.54. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of 33.28 and a beta of 0.65. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27.

Collegium Pharmaceutical declared that its board has initiated a share buyback plan on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Gino Santini sold 5,405 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $37.19, for a total value of $201,011.95. Following the transaction, the director owned 95,042 shares of the company's stock, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 16,389 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares in the company, valued at $3,959,052.73. This represents a 13.66% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,792 shares of company stock worth $2,084,207. 2.51% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of COLL. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Collegium Pharmaceutical by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock worth $1,902,000 after acquiring an additional 7,063 shares during the period. GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical by 8,947.4% in the first quarter. GAMMA Investing LLC now owns 17,552 shares of the specialty pharmaceutical company's stock valued at $524,000 after purchasing an additional 17,358 shares during the last quarter. Rhumbline Advisers grew its holdings in Collegium Pharmaceutical by 3.1% in the first quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company's stock valued at $3,332,000 after purchasing an additional 3,400 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Collegium Pharmaceutical by 4.5% in the first quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after purchasing an additional 477 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Collegium Pharmaceutical by 4.2% in the first quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company's stock valued at $426,000 after purchasing an additional 578 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.